Yulithira Tablet
Product Images NDC 82249-613

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Yulithira (NDC 82249-613). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Civicascript, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Yulithira 01)

Chemical structure of Everolimus, the active ingredient in Yulithira. The diagram shows the molecular framework commonly associated with this drug substance.*

FDA Label Image

Figure 1 (Yulithira 02)

A Kaplan-Meier survival curve graph depicting progression-free survival probability (%) over time in months for Everolimus 10 mg plus exemestane versus placebo plus exemestane. The graph shows higher survival probability for the Everolimus group with detailed hazard ratio, median survival times, and logrank p value annotations.*

FDA Label Image

Figure 2 (Yulithira 03)

A Kaplan-Meier survival probability plot comparing Everolimus (N=207) and Placebo (N=203) over time in months. The graph shows survival probability on the y-axis and time in months on the x-axis, with censoring times indicated. The plot notes hazard ratio, confidence intervals, and median survival times: Everolimus at 11.04 months and Placebo at 4.60 months.*

FDA Label Image

Figure 3 (Yulithira 04)

A Kaplan-Meier survival curve chart showing the probability (%) of event-free status over time in months for patients treated with Everolimus plus BSC (best supportive care) versus Placebo plus BSC. The chart includes a table listing the number of patients still at risk at multiple time points up to 30 months for each treatment group.*

FDA Label Image

Figure 4 (Yulithira 05)

Kaplan-Meier survival curve comparing Everolimus versus placebo over time (months) with probability (%) on the y-axis. The chart includes hazard ratio, 95% confidence interval, and logrank p value, showing Everolimus median survival of 4.9 months compared to placebo median of 1.9 months. It also marks censoring times and sample sizes (Everolimus N=277, Placebo N=139).*

FDA Label Image

Principal Display Panel (2.5 mg Tablet Bottle Label)

Yulithira (everolimus) tablets 2.5 mg label showing 30 tablets per container. The label includes storage instructions, dosing reference, and manufacturer information for CivicaScript, LLC. It displays NDC 82249-610-30, a barcode, and a QR code linking to product information online. The label cautions to keep out of reach of children and notes the product is Rx only.*

FDA Label Image

Principal Display Panel (5 mg Tablet Bottle Label)

Yulithira 5 mg (everolimus) tablets label for oral use. The label indicates each tablet contains 5 mg of everolimus with a package containing 30 tablets. It includes dosage storage instructions, distributor and manufacturer information, barcode, QR code, and is labeled as Rx only. The product is labeled under CivicaScript, LLC.*

FDA Label Image

Principal Display Panel (7.5 mg Tablet Bottle Label)

Yulithira 7.5 mg tablets packaging label showing everolimus as the active ingredient. The label indicates oral use with a quantity of 30 tablets. Storage instructions specify controlled room temperature. The labeler is CivicaScript, LLC with manufacturing by Breckenridge Pharmaceutical, Inc. A barcode, QR code, and NDC 82249-612-30 are visible along with drug dosage and safety information.*

FDA Label Image

Principal Display Panel (10 mg Tablet Bottle Label)

Label for Yulithira (everolimus) tablets 10 mg by CivicaScript, LLC. The label indicates 30 oral tablets per package, each containing 10 mg everolimus. It includes storage instructions and Rx only designation. The label features a barcode, QR code linking to civicascript.com, and manufacturer details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.